Want to see NEUP full AI Analyst Report?
Total Valuation
Neuphoria Therapeutics has a market cap or net worth of $18.18M. The enterprise value is $3.89T.
Market Cap$18.18M
Enterprise Value$3.89T
Share Statistics
Neuphoria Therapeutics has 5,411,334 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,411,334
Owned by Insiders―
Owned by Institutions25.84%
Financial Efficiency
Neuphoria Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.03%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.03%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee1.17M
Profits Per Employee-13.45B
Employee Count1
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuphoria Therapeutics is ―. Neuphoria Therapeutics’s PEG ratio is -0.00116.
PE Ratio―
PS Ratio16.36
PB Ratio<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio-0.00116
Income Statement
In the last 12 months, Neuphoria Therapeutics had revenue of 1.17M and earned -13.45M in profits. Earnings per share was -3.06.
Revenue1.17M
Gross Profit511.21K
Operating Income-9.81M
Pretax Income-13.59M
Net Income-13.45M
EBITDA-9.15M
Earnings Per Share (EPS)-3.06
Cash Flow
In the last 12 months, operating cash flow was -12.35B and capital expenditures 0.00, giving a free cash flow of -12.35B billion.
Operating Cash Flow-12.35B
Free Cash Flow-12.35B
Free Cash Flow per Share-2.28K
Dividends & Yields
Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.52
52-Week Price Change-26.64%
50-Day Moving Average3.61
200-Day Moving Average4.17
Relative Strength Index (RSI)40.36
Average Volume (3m)19.56K
Important Dates
Neuphoria Therapeutics upcoming earnings date is Sep 29, 2025, TBA (Confirmed).
Last Earnings DateFeb 20, 2025
Next Earnings DateSep 29, 2025
Ex-Dividend Date―
Financial Position
Neuphoria Therapeutics as a current ratio of 27.85, with Debt / Equity ratio of 0.14%
Current Ratio27.85
Quick Ratio27.85
Debt to Market Cap<0.01
Net Debt to EBITDA2.17K
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuphoria Therapeutics has paid -139.17K in taxes.
Income Tax-139.17K
Effective Tax Rate0.01
Enterprise Valuation
Neuphoria Therapeutics EV to EBITDA ratio is 2.17K, with an EV/FCF ratio of 1.61.
EV to Sales-16.90K
EV to EBITDA2.17K
EV to Free Cash Flow1.61
EV to Operating Cash Flow1.61
Balance Sheet
Neuphoria Therapeutics has $19.87M in cash and marketable securities with $34.34K in debt, giving a net cash position of $19.83M billion.
Cash & Marketable Securities$19.87M
Total Debt$34.34K
Net Cash$19.83M
Net Cash Per Share$3.66
Tangible Book Value Per Share$3.86K
Margins
Gross margin is 43.54%, with operating margin of -835.53%, and net profit margin of -1145.66%.
Gross Margin43.54%
Operating Margin-835.53%
Pretax Margin-1157.51%
Net Profit Margin-1145.66%
EBITDA Margin-779.07%
EBIT Margin-835.53%
Analyst Forecast
The average price target for Neuphoria Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―